BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with BPC 157 for athletes and injury treatment: Science, safety, and legal concerns Hims & Hers stock rises as FDA schedules peptide review The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them US FDA to convene expert panel to review wider access to some peptides Reuters